Back to the full story8 sources · Moderna and Merck’s mRNA Melanoma Vaccine Looks Like a Game Changer◆ Analytics
Moderna and Merck’s mRNA Melanoma Vaccine Looks Like a Game Changer
Deterministic text analytics computed across all 8 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
modernacancermrnavaccinemerckmelanomatrialtreatmentskinexperimental
Top phrases
moderna and merckcancer vaccineskin cancermrna cancermoderna and merck sharesmrna cancer vaccinemelanoma vaccinelandmark momentmerck shareslate stage
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Merck · 6 sources
- Moderna · 6 sources
- Keytruda · 3 sources
- Merck's · 2 sources
- People · 2 sources
Unique to one source
- How Moderna's · CBS News
- CBS News · CBS News
- Gounder · CBS News
- Cancer · CNBC
- Trump · Axios
- COVID · Axios
- Food · Axios
- Phase · Ars Technica
- Pharmaceutical · Ars Technica
- The Phase · Ars Technica
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "People given the experimental vaccine with standard treatment lived longer without their cancer returning, the companies reported this week." · Gizmodo
- "Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors." · PBS NewsHour
- "Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer." CBS News medical correspondent Dr." · CBS News
- "Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer."" · CBS News
- "Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer." · CBS News — Top
- "The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells The combined drug works by nudging the body’s own immune system to make proteins that attack and destroy melanoma cells" · Scientific American
- "The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone." · CNBC
- "Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial." · Axios